Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Researchers from the Huntington's Disease Center, UCL Queen Square Institute of Neurology, and UK DRI at UCL have taken major ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome ...

A new study reveals that entacapone, a drug used to treat Parkinson’s disease, significantly disrupts the gut microbiome by ...

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...

Oligonucleotide therapies are among the most promising biological therapeutics. They target disease at a different stage of ...

Rodriguez has filed a new measure that would allow patients suffering from severe illnesses to have individualized treatment options.

Alfa Chemistry has made a remarkable stride in the field of synthetic biology with the recent renewal of its oligonucleotide series products. This updated lineup includes a range of advanced ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center and School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Rd, Beijing 100191, China ...

Cure Rare Disease has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide therapy for ...